iQure Pharma Inc.
iQure Pharma is a clinical-stage biotech company focused on developing therapies for CNS disorders by restoring glutamate homeostasis. Their approach targets astrocytic functions, specifically enhancing the glutamate transporter EAAT2, to break the cycle of excitotoxicity that drives neuronal damage across various CNS conditions. Their lead asset, iQ-007, is a first-in-class, orally available small molecule in Phase 1 clinical development for treatment-resistant epilepsy, with potential applications in neurodegeneration and pain. The company collaborates with academic and industry partners, and is supported by investors including Ventura BioMed, OKG Capital, and others.
Industries
Nr. of Employees
small (1-50)
iQure Pharma Inc.
Products
Clinical-stage EAAT2 positive allosteric modulator (lead compound, Phase 1)
Orally bioavailable small-molecule positive allosteric modulator of EAAT2 designed to enhance glutamate uptake (reported ~2.5-fold increase in uptake in preclinical assays); advanced into Phase 1 first-in-human studies for epilepsy and being evaluated across other CNS indications.
Preclinical EAAT2-targeted small-molecule series for pain and neurodegeneration
Next-generation small-molecule programs targeting EAAT2 tailored to disease-specific mechanisms in pain, ALS, and neurodegeneration (preclinical stages: discovery, lead identification, preclinical testing).
Clinical-stage EAAT2 positive allosteric modulator (lead compound, Phase 1)
Orally bioavailable small-molecule positive allosteric modulator of EAAT2 designed to enhance glutamate uptake (reported ~2.5-fold increase in uptake in preclinical assays); advanced into Phase 1 first-in-human studies for epilepsy and being evaluated across other CNS indications.
Preclinical EAAT2-targeted small-molecule series for pain and neurodegeneration
Next-generation small-molecule programs targeting EAAT2 tailored to disease-specific mechanisms in pain, ALS, and neurodegeneration (preclinical stages: discovery, lead identification, preclinical testing).
Services
Collaborative research partnerships for EAAT2-targeted programs
Collaborative preclinical and translational research partnerships with academic and industry groups to advance EAAT2-modulating small molecules.
Collaborative research partnerships for EAAT2-targeted programs
Collaborative preclinical and translational research partnerships with academic and industry groups to advance EAAT2-modulating small molecules.
Expertise Areas
- CNS drug discovery
- Astrocyte-targeted therapeutics (glutamate homeostasis)
- Preclinical pharmacology and translational models
- Small-molecule medicinal chemistry
Key Technologies
- Positive allosteric modulation of membrane transporters (EAAT2)
- Small-molecule medicinal chemistry
- Oral drug formulation
- In vivo epilepsy models